High dose therapy with autologous blood stem cells support is a promising treatment for patients with high risk breast cancer, stage 2 (with more than 9 involved lymph nodes), imflammatory breast cancer and possibly for metastatic breast cancer too.
High dose therapy with autologous blood stem cells support is a promising treatment for patients with high risk breast cancer, stage 2 (with more than 9 involved lymph nodes), imflammatory breast cancer and possibly for metastatic breast cancer too.
Preliminary data obtained in uncontrolled studies are positive and show a 60 to 70% disease-free-survival in the adjuvant setting for patients with stage 2 more than 9 lymph nodes involved breast cancer at 5 years.
Confirmatory randomized studies are still ongoing. Results will be available in one to two years.
The interest in high dose therapy and autologous blood stem cell transplant in metastatic breast cancer was rekindled by a randomized study by Bezwoda who could show a significant survival advantage of patients in the high dose arm at the time of publication. The further follow-up of two more years revealed that still of the same 20% disease-free at the time of publication continue in progressionfree-survival. Several studies in the United States, Germany and other European countries following this lead.
The Hamburg-Düsseldorf-Study explores single high dose therapy with tandem high dose therapy of Cytoxan, Thiotepa, Carboplatin in chemo-sensitive patients with metastatic breast cancer.
Recommended induction regimen is Epirubicin and Paclitacel, other standard therapies are admissible. To this point more than 110 patients entered this protocol.
Therapy associated mortality of high dose therapy is below 5%, the morbidity is acceptable, major toxicity is seen with mucositis requiring morphine therapy and fever of unknown origin. Quality of life after completed, high dose therapy appears to be good.
Questions not yet adressed in these studies are:
(1) Optimal strategies of high dose therapy (early treatment versus late intensification) (2) Single versus tandem high dose therapy (3) Prognostic value of tumor contamination of the blood stem cell graft and bone marrow (4) Impact on purging on relapse (5) Immunmodulation after transplant including allogeneic blood stem cell transplant in breast cancer (6) Documentation and reduction of long term side effect of high dose therapy.
S17
To develop high dose therapy in breast cancer and to answer the relevant clinical question requires optimal cooperation between study-groups, pilot-centers, investigators, gyncologist, oncologist, professional societies and insurances. Introduction: In contrast to malignancies such as CML or AML the contribution of contaminating cancer cells in leukaphereses products of breast cancer patients to relapse with metastatic disease after high-dose therapy and stem cell reinfusion has not been clarified yet. 1 Data from theliterature about the contamination frequency show a wide variation. The tumour cell load of LP products ist mostly described as low. 2 Here we present our data about cancer cell contamination in 124 aphereses products from 62 women with breast cancer. Material and methods: Stem cells were mobilised with G-CSF (10 g to 24 g over four to five days) from steadystate haemopoiesis after conventional dose anthracyclincontaining chemotherapy. 124 samples were obtained from women with nodal-positive high-risk cancer (n = 64), from women with chemosensitive metastatic cancer (n = 38), and from women with inflammatory disease (n = 20). In two cases no detailed data about the disease were known. 107 samples were searched immunocytochemically for breast cancer cells. A median of 106 (0.8-10*106)MNCs were spun onto cytospin slides. Cancer cells were detected either by antibody KL1 or by FAB-fragment A45/B-B3 and subsequently stained in a colour reaction. 36 samples were examined by cytotokeratin-19 rtPCR as previously described. 3 A median of 5*107 (1-10*107) MNCs from 37 samples were additionally subjected to immunomagnetical tumour cell selection with anti-HEA125 magnetic microbeads. Positive fractions were searched immunocytochemically for cancer cells. In some cases, a double stain technique with anti-cytokeratin and anti-UPA-R was performed. Results: A total of 64/124 scored tumour cell positive by immunocytochemistry or cytokeratin-19 rtPCR without preceding enrichment technique. Tumour cells were found in the aphereses products by immunocytochemistry alone in 58/107 (44,9%) samples. The cancer cell load detected without immunomagnetical enrichment was low with a maximum of 4 cells per million MNCs investigated. 14/23 (37.8%) of the specimens subjected to HEA125-enrichment scored positive by conventional immunocytochemistry. HEA125-selection increased the positivity rate to 32/37 (86.5%). A median of 5 (0-34) tumour cells were detected per sample. However, the tumour cell count per 106 MNC subjected to selection was low with a median of 0.12 and a range from 0 to 3,4. Anti-cytokeratin-APAAP7anti-CD87-immunogold double stain technique was performed from 0 to 3.4. Anti-cytokeratin-APAAP/anti-CD87-to selection was low with a median of 0.12 and a range preliminary to some samples. This experiment revealed that some but not all cancer cells express the urokinase-like plasminogenactivator receptor on their surface. Discussion: The rate of contaminating cancer cells in leukaphereses samples from breast cancer patients depends directly from the amount of MNCs investigated.
S9d: Disseminated Tumor Cells in Breast Cancer
Our data indicate that tumour cell contamination of LPs from women with breast cancer is ubiquitous. The likelihood that these cells may contribute uniformly to relapse with distant metastases after reinfusion seems to be low. Several investigators have shown that the phenotype of tumour cells shows wide biological and phenotypical variations. 4, 5 In a preliminary study we investigated the expression of CD87 on circulating cancer cells. It has been suggested that this protease activator has a central position in the process of metastases. We could show that CD87 is expressed on some but not on all circulating breast cancer cells. Phenotype-characterisation studies might be one way to determine the biological aggressiveness of micrometastatic cancer cells in vivo.
